David Veenstra

The cost-effectiveness of next generation sequencing in colorectal cancer

James Buchanan Paper review , , , , , , , ,

So, apologies again for the radio silence. Good news though: the PhD has finally been submitted! That’s not quite the end of that chapter in my life though, as I still have a viva to complete and six more publications to prepare to add to the two that have been published in the last 18 months or so. Hopefully I’ll be able to share more of my PhD outputs from the start of 2016 onwards, depending (of course) on the vagaries of the peer-review process.

Anyway, I now have time to read and then write about all of the publications that I’ve been putting to one side over the last few months. I’m going to start with a paper by Carlos Gallego et al. which was published in JCO in May, and which considered the cost-effectiveness of next generation sequencing (NGS) panels for the diagnosis of colorectal cancer and polyposis (CRCP) syndromes.

Continue reading →

Incidental findings in genomic sequencing: a health economics perspective

James Buchanan Paper review , , , , , , , ,

When this blog began, I mentioned that I would be happy to publish posts by other researchers: different opinions and healthy debate are both welcome here. I’m therefore very pleased to introduce a colleague of mine at the University of Oxford, Jilles Fermont, who discusses some recently published articles on incidental findings in genomic sequencing from a health economics perspective.

Incidental findings (IFs) are a topic of considerable debate, not just in genomic medicine but also in other fields of medicine. To date, few health economists have undertaken any work in this area, but a recent burst of publications suggests that this is beginning to change. This post is primarily prompted by the publication of a paper in Genetics in Medicine earlier in November titled “The cost-effectiveness of returning incidental findings from next-generation genomic sequencing”, authored by Bennette and colleagues. The authors intended to evaluate the clinical and economic impact of IFs in genomic sequencing. The cost-effectiveness analysis (CEA) is restricted and has limitations (see below) but, as the authors already indicated, it is much more of an exploratory study providing policy recommendations on how to deal with IFs from genomic sequencing. Also, it is not a CEA of next-generation sequencing (NGS) but that of the return of IFs. Despite these caveats, it remains an interesting and relevant paper. Those involved or interested in this field are recommended to read it.

Continue reading →